(33%)
Other 45% 13% 20%
(11%) 19% (6%)
Nine Months Ended
September 30,
2007
United
States Europe Total
Sales:
PROVIGIL $593,394 $39,171 $632,565
GABITRIL 39,814 6,268 46,082
CNS 633,208 45,439 678,647
ACTIQ 157,097 28,638 185,735
Generic OTFC 97,562 - 97,562
FENTORA 101,224 - 101,224
Pain 355,883 28,638 384,521
Other 53,867 170,767 224,634
$1,042,958 $244,844 $1,287,802
2006
United
States Europe Total
Sales:
PROVIGIL $494,047 $29,219 $523,266
GABITRIL 41,291 3,510 44,801
CNS 535,338 32,729 568,067
ACTIQ 452,175 19,213 471,388
Generic OTFC - - -
FENTORA - - -
Pain 452,175 19,213 471,388
Other 41,661 152,436 194,097
$1,029,174 $204,378 $1,233,552
'/>"/>
SOURCE Cephalon, Inc. Copyright©2007 PR Newswire. All rights reserved | |
Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 Related biology technology :1.
Cephalon Announces Positive Results from a Pivotal Study of FENTORA in Opioid-tolerant Patients with Non-cancer Breakthrough Pain2.
Cephalon, Inc. Announces Agreement to Acquire AMRIX, A Once-Daily Extended-Release Muscle Relaxant3.
Cephalon Reinforces Important Prescribing and Dosing Information for FENTORA4.
Cephalon Submits New Drug Application for TREANDA for the Treatment of Chronic Lymphocytic Leukemia5.
Cephalon Quarterly Conference Call Invitation6.
Dendreon Announces Publication of Phase 1 Study Highlighting Immunologic and Clinical Activity of Lapuleucel-T (Neuvenge(R)) in Advanced Breast Cancer Patients7.
YM BIOSCIENCES ANNOUNCES COMPLIANCE WITH AIM RULE 268.
Emisphere Technologies, Inc. Announces Pricing of Registered Direct Offering9.
BioLife Solutions Announces Exclusive CryoStor(TM) Supply Agreement With the New England Cryogenic Center, Inc.10.
Carrington Announces Nasdaq Communication; Prepares for Shares to Be Quoted on the OTC Bulletin Board and Pink Sheets11.
China Kangtai Cactus Biotech Files 2nd Quarter 2007 10QSB and Announces Unaudited Quarterly Results